APYX Stock Forecast & Price Target

Apyx Medical Corp has demonstrated a strong performance in its Surgical Aesthetics segment, with revenue expectations set between $43.0 million and $45.0 million for the year, reflecting a year-over-year growth of 14% at the midpoint. Management has raised its full-year revenue guidance from $50.0-52.0 million to $50.5-52.5 million, primarily driven by improved execution and rising demand trends in the surgical aesthetics market. The company has also reported a 12% increase in quarterly revenue, largely attributable to the successful launch of the AYON product and heightened sales of single-use handpieces, prompting an overall revenue estimate increase for FY2026 to $58.0 million.

Apyx Medical Corp's negative outlook stems from a projected decline in Original Equipment Manufacturing (OEM) sales, now estimated at approximately $7.5 million, reflecting reduced sales volumes that are concerning for revenue stability. The company has experienced ongoing volatility in its Surgical Aesthetics segment, which has historically constituted over 80% of its revenue, compounded by challenges such as regulatory issues and the recent uptick in GLP-1 usage impacting the aesthetics market. Furthermore, Apyx's cash position declined from $29.3 million at the end of the second quarter in 2025 to $25.1 million at the end of the third quarter, highlighting cash flow pressures amidst declining revenues.